![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 24, 2017 11:00:41 AM
Recent ATOS News
- Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer • GlobeNewswire Inc. • 09/10/2024 12:30:00 PM
- Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:30:00 PM
- Atossa Therapeutics Granted Additional Patent Protection for Endoxifen • GlobeNewswire Inc. • 08/28/2024 12:30:00 PM
- Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 08/21/2024 12:30:00 PM
- Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 01:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:00:09 PM
- Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 12:30:00 PM
- Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer • GlobeNewswire Inc. • 07/22/2024 12:30:00 PM
- Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer • GlobeNewswire Inc. • 07/02/2024 08:15:00 PM
- Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Atossa Set to Join Russell 3000® Index Effective June 28, 2024 • GlobeNewswire Inc. • 06/17/2024 12:30:00 PM
- Atossa to Present at the Sidoti Small-Cap Investor Conference • GlobeNewswire Inc. • 06/05/2024 12:30:00 PM
- Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model • GlobeNewswire Inc. • 05/28/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/24/2024 04:15:32 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/23/2024 01:00:04 PM
- Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 05/14/2024 08:46:30 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/13/2024 08:05:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 01:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 01:00:12 PM
- Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 12:50:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 01:00:05 PM
- Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines • GlobeNewswire Inc. • 05/07/2024 12:30:00 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM